Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Angiosarcoma
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Primary cardiac angiosarcoma ==== Primary cardiac angiosarcoma is an angiosarcoma that arises in the [[heart]]. Despite being very rare they are the most common malignant [[Primary tumors of the heart|primary heart tumor]] with 10β25%<ref name=":2">{{Cite journal|last1=Patel|first1=Swetal Dilip|last2=Peterson|first2=Ashley|last3=Bartczak|first3=Artur|last4=Lee|first4=Sarah|last5=Chojnowski|first5=SΕawomir|last6=Gajewski|first6=Piotr|last7=Loukas|first7=Marios|date=2014|title=Primary cardiac angiosarcoma β a review|journal=Medical Science Monitor|language=en|volume=20|pages=103β109|doi=10.12659/MSM.889875|pmid=24452054|pmc=3907509}}</ref><ref name="Angiosarcoma" /> of cases being angiosarcomas. Symptoms may include shortness of breath, chest pain (46%<ref name=":2" />), [[hypotension]] and [[Syncope (medicine)|syncope]]. [[Superior vena cava syndrome]] is reportedly a [[Complication (medicine)|complication]] of cardiac angiosarcoma.<ref name="headtotoe" /> Due to the non-specificity of symptoms and rarity of the disease it is often missed by doctors and initial diagnosis may be delayed. A 2012 study reported that 56% of patients presented with [[pericardial effusion]] with or without [[cardiac tamponade]].<ref name=":2" /> The most common finding on [[Medical imaging|imaging]] is [[cardiomegaly]]. Prognosis is generally very poor with a mean survival rate of three months to four years following diagnosis.<ref name="headtotoe" /> Metastasis at time of diagnosis is common.<ref name=":2" />
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)